Affymax Files $100M Mixed Securities Shelf

Law360, New York (October 2, 2009, 5:30 PM EDT) -- Biopharmaceutical company Affymax Inc. filed a $100 million mixed securities shelf registration with the U.S. Securities and Exchange Commission on Friday, hoping to use the proceeds of the sale for the further development and marketing of anemia drug Hematide.

The registration allows for future sales in any combination of common stock, preferred stock, debt securities, warrants and units.

The company is developing Hematide, which will be used to treat anemia related to chronic renal failure. It is the company's only current drug candidate.

Affymax intends to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.